The American Society of Clinical Oncology (ASCO) announced results
from four major studies to be presented at ASCO's 51st Annual Meeting,
May 29-June 2, in Chicago. Findings showed that use of a widely
available Vitamin pill reduces the risk of non-melanoma Skin Cancers;
that early chemotherapy extends the lives of men with advanced Prostate Cancers; and that new therapies can improve outcomes for children with a
rare form of Kidney Cancer and adults with relapsed multiple myeloma.
"Trials like these are engines of progress for people with cancer of
all ages," said ASCO President Peter Paul Yu, MD, FACP, FASCO. "In just
four studies, we see the potential to spare thousands of people the
stress and complications of a new cancer diagnosis, and to extend the
lives of children and adults facing cancer in its most daunting forms.
At ASCO's meeting in Chicago, we'll continue to see the transformative
power of investments in cancer research and care."
"We're in an era of cutting-edge precision medicine, yet we can
still achieve meaningful progress with conventional treatments," said
Gregory A. Masters, MD, FACP, FASCO, Chair of ASCO's Cancer
Communications Committee. "Thanks to a deeper understanding of cancer
biology, we have a potential new targeted therapy for multiple myeloma,
and can better tailor treatment for kids with Wilms tumor. At the same
time, a simple vitamin pill and a long-available chemotherapy are being
put to work in different ways to improve the lives of patients."
No comments:
Post a Comment